In brief, the CD62L on CD62L+ myeloid DC associated with the guanosine ribonucleotides de novo biosynthesis increases the risk of IBD by 13.8%; the HLA DR on CD14+ monocyte associated with phylum Proteobacteria accounts for a 21% reduction in IBD risk. The gene discussed is SELL; the disease is inflammatory bowel disease.